Market Cap 453.56M
Revenue (ttm) 197.61M
Net Income (ttm) -130.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -65.95%
Debt to Equity Ratio 2.38
Volume 6,200
Avg Vol 29,416
Day's Range N/A - N/A
Shares Out 94.89M
Stochastic %K 6%
Beta 1.77
Analysts Strong Sell
Price Target $12.20

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 2 28 07 37 10
Fax: 33 2 28 07 37 11
Website: valneva.com
Address:
6 rue Alain Bombard, Saint-Herblain, France
Jhoooon
Jhoooon Jul. 22 at 6:22 PM
$BMEA $MLTX $VALN 1 thing is true though. Creisi disappeared from bmea months ago, while he still posts hugely here. I do not care at all by the way, just pointing out that fact
1 · Reply
Richmonddawg
Richmonddawg Jul. 22 at 4:33 PM
$BMEA $MLTX $VALN There is nothing to talk about until data comes out. Or, maybe he is just sick of assholes like you, that does not own any stock, but comes on here everyday just to be an ass.
2 · Reply
Richmonddawg
Richmonddawg Jul. 22 at 4:31 PM
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 22 at 4:16 PM
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 22 at 2:35 PM
$BMEA $MLTX $VALN Where is our favorite pump artist, @creisi? 🎭 Remember when he posted 500 times a month on $BMEA, claiming he held a casual 750,000 shares? Fast forward to today: weeks of radio silence. He either never owned a single share or pulled off the ultimate magic trick—dumping everything incognito and vanishing into thin air. Classic! Don't worry, the sequel is already coming to $MLTX. Same script, same theatrical hype, same "dithyrambic" posts to pump the price before he hits the eject button, leaving retail investors holding the bag. It’s a beautifully executed "rinse and repeat" cycle designed to fill his own pockets while blind believers fund his exit. Kudos to the performance, @creisi. We see right through the act. To the rest of you: stop worshiping these hype-gods before you end up as the next permanent resident of Bagholder Land
2 · Reply
G101SPM
G101SPM Jul. 2 at 5:10 PM
$VALN $5.25 ask. BUY/10X ADD TO LONG POSITION to reset net cost at $5.85. RETAIN EXIT AT $25.00 (long trem). OVERVIEW: In March 2026, VALN referred topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405.; missed on statistical significance, noting 73.2% efficacy at 28 days post-dose did not meet the required threshold on the lower bound of the confidence interval. Afterwards, Pfizer and Valneva SE (announced the topline reults from the Phase 3 VALOR trial showing 73.2% efficacy from 28 days post-dose and 74.8% efficacy from one day post-dose in reducing confirmed Lyme disease cases versus placebo. Pfizer and Valneva have said that fewer cases than expected were recorded, and the first pre-specified statistical criterion was not met, but noted the second analysis showed a confidence interval lower bound above 20, supporting plans for regulatory submissions.
0 · Reply
Barry64
Barry64 Jun. 17 at 11:19 AM
$VALN What is the timeframe for submission of Outdoor Recreationists (VALOR) (NCT05477524) to regulatory agencies for Lyme disease? I couldn't find any info on their website.
0 · Reply
kogklasse
kogklasse Jun. 4 at 9:56 AM
$VALN @Creisi. If you have time and feel like it. Do you have any new stance or take on VALN? Thank you in advance 👏
2 · Reply
RogueEngineer
RogueEngineer May. 30 at 12:28 AM
1 · Reply
DaxCo
DaxCo May. 26 at 5:02 PM
$VALN https://finance.yahoo.com/sectors/healthcare/articles/lilly-acquire-three-vaccine-developers-105831332.html
0 · Reply
Latest News on VALN
Valneva SE Extraordinary Shareholders Meeting Transcript

2026-06-25T18:00:08.000Z - 4 weeks ago

Valneva SE Extraordinary Shareholders Meeting Transcript


Valneva files to sell 31.79M ordinary shares for holders

2026-06-04T21:10:13.000Z - 7 weeks ago

Valneva files to sell 31.79M ordinary shares for holders


Valneva SE Registration statement: Registration filing

Jun 4, 2026, 8:00 AM EDT - 7 weeks ago

Valneva SE Registration statement: Registration filing


Valneva SE Slides: Investor presentation

Jun 3, 2026, 2:00 AM EDT - 7 weeks ago

Valneva SE Slides: Investor presentation


Valneva Q1 Earnings Call Highlights

Wed, 13 May 2026 15:12:54 -0400 - 2 months ago

Valneva Q1 Earnings Call Highlights


Valneva SE Earnings Call Transcript: Q1 2026

May 13, 2026, 9:00 AM EDT - 2 months ago

Valneva SE Earnings Call Transcript: Q1 2026


Valneva SE Earnings release: Q1 2026

May 13, 2026, 9:00 AM EDT - 2 months ago

Valneva SE Earnings release: Q1 2026


Valneva SE Slides: Q1 2026

May 13, 2026, 9:00 AM EDT - 2 months ago

Valneva SE Slides: Q1 2026


Valneva SE Quarterly report: Q1 2026

May 13, 2026, 9:00 AM EDT - 2 months ago

Valneva SE Quarterly report: Q1 2026


Valneva downgraded to Sell from Neutral at Goldman Sachs

2026-04-22T08:30:42.000Z - 3 months ago

Valneva downgraded to Sell from Neutral at Goldman Sachs


Valneva price target lowered to $11 from $13 at Guggenheim

2026-04-16T10:54:32.000Z - 3 months ago

Valneva price target lowered to $11 from $13 at Guggenheim


Valneva SE Earnings Call Transcript: Q4 2025

Mar 18, 2026, 10:00 AM EDT - 4 months ago

Valneva SE Earnings Call Transcript: Q4 2025


Valneva SE Earnings release: Q4 2025

Mar 18, 2026, 10:00 AM EDT - 4 months ago

Valneva SE Earnings release: Q4 2025


Valneva SE Earnings release: Q4 2025

Mar 18, 2026, 10:00 AM EDT - 4 months ago

Valneva SE Earnings release: Q4 2025


Valneva SE Annual report: Q4 2025

Mar 18, 2026, 10:00 AM EDT - 4 months ago

Valneva SE Annual report: Q4 2025


Valneva SE Slides: Q4 2025

Mar 18, 2026, 10:00 AM EDT - 4 months ago

Valneva SE Slides: Q4 2025


Valneva SE Annual report: Q4 2025

Mar 18, 2026, 10:00 AM EDT - 4 months ago

Valneva SE Annual report: Q4 2025


Elaris FlexCo secures exclusive global license from Valneva

2026-03-18T12:19:54.000Z - 4 months ago

Elaris FlexCo secures exclusive global license from Valneva


Valneva SE Slides: Company presentation

Mar 4, 2026, 2:00 AM EST - 5 months ago

Valneva SE Slides: Company presentation


Valneva to Participate in Upcoming Investor Conferences

Mar 2, 2026, 11:45 AM EST - 5 months ago

Valneva to Participate in Upcoming Investor Conferences

VALN


Valneva SE Earnings release: Q4 2025

Feb 19, 2026, 1:00 AM EST - 5 months ago

Valneva SE Earnings release: Q4 2025


Valneva SE Slides: Investor presentation

Jan 21, 2026, 2:00 AM EST - 6 months ago

Valneva SE Slides: Investor presentation


Valneva withdraws BLA, IND application for Ixchiq in U.S.

2026-01-19T19:15:14.000Z - 6 months ago

Valneva withdraws BLA, IND application for Ixchiq in U.S.


Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Jan 19, 2026, 12:00 PM EST - 6 months ago

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

VALN


Valneva SE - Declaration of voting rights - December 2025

Jan 8, 2026, 12:30 PM EST - 7 months ago

Valneva SE - Declaration of voting rights - December 2025

VALN


Valneva to Further Consolidate its Operations in France

Nov 26, 2025, 11:30 AM EST - 8 months ago

Valneva to Further Consolidate its Operations in France

VALN


Valneva SE Earnings Call Transcript: Q3 2025

Nov 20, 2025, 9:00 AM EST - 8 months ago

Valneva SE Earnings Call Transcript: Q3 2025


Valneva SE Quarterly report: Q3 2025

Nov 20, 2025, 9:00 AM EST - 8 months ago

Valneva SE Quarterly report: Q3 2025


Valneva SE Earnings release: Q3 2025

Nov 20, 2025, 9:00 AM EST - 8 months ago

Valneva SE Earnings release: Q3 2025


Valneva SE Slides: Q3 2025

Nov 20, 2025, 9:00 AM EST - 8 months ago

Valneva SE Slides: Q3 2025


Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:43 AM EDT - 11 months ago

Johnson Fistel Investigates Valneva Following FDA Suspension

VALN


FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:16 AM EDT - 11 months ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

VALN


Valneva SE (ADR) trading halted, news pending

2025-08-22T18:50:25.000Z - 1 year ago

Valneva SE (ADR) trading halted, news pending

VALN


Jhoooon
Jhoooon Jul. 22 at 6:22 PM
$BMEA $MLTX $VALN 1 thing is true though. Creisi disappeared from bmea months ago, while he still posts hugely here. I do not care at all by the way, just pointing out that fact
1 · Reply
Richmonddawg
Richmonddawg Jul. 22 at 4:33 PM
$BMEA $MLTX $VALN There is nothing to talk about until data comes out. Or, maybe he is just sick of assholes like you, that does not own any stock, but comes on here everyday just to be an ass.
2 · Reply
Richmonddawg
Richmonddawg Jul. 22 at 4:31 PM
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 22 at 4:16 PM
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 22 at 2:35 PM
$BMEA $MLTX $VALN Where is our favorite pump artist, @creisi? 🎭 Remember when he posted 500 times a month on $BMEA, claiming he held a casual 750,000 shares? Fast forward to today: weeks of radio silence. He either never owned a single share or pulled off the ultimate magic trick—dumping everything incognito and vanishing into thin air. Classic! Don't worry, the sequel is already coming to $MLTX. Same script, same theatrical hype, same "dithyrambic" posts to pump the price before he hits the eject button, leaving retail investors holding the bag. It’s a beautifully executed "rinse and repeat" cycle designed to fill his own pockets while blind believers fund his exit. Kudos to the performance, @creisi. We see right through the act. To the rest of you: stop worshiping these hype-gods before you end up as the next permanent resident of Bagholder Land
2 · Reply
G101SPM
G101SPM Jul. 2 at 5:10 PM
$VALN $5.25 ask. BUY/10X ADD TO LONG POSITION to reset net cost at $5.85. RETAIN EXIT AT $25.00 (long trem). OVERVIEW: In March 2026, VALN referred topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405.; missed on statistical significance, noting 73.2% efficacy at 28 days post-dose did not meet the required threshold on the lower bound of the confidence interval. Afterwards, Pfizer and Valneva SE (announced the topline reults from the Phase 3 VALOR trial showing 73.2% efficacy from 28 days post-dose and 74.8% efficacy from one day post-dose in reducing confirmed Lyme disease cases versus placebo. Pfizer and Valneva have said that fewer cases than expected were recorded, and the first pre-specified statistical criterion was not met, but noted the second analysis showed a confidence interval lower bound above 20, supporting plans for regulatory submissions.
0 · Reply
Barry64
Barry64 Jun. 17 at 11:19 AM
$VALN What is the timeframe for submission of Outdoor Recreationists (VALOR) (NCT05477524) to regulatory agencies for Lyme disease? I couldn't find any info on their website.
0 · Reply
kogklasse
kogklasse Jun. 4 at 9:56 AM
$VALN @Creisi. If you have time and feel like it. Do you have any new stance or take on VALN? Thank you in advance 👏
2 · Reply
RogueEngineer
RogueEngineer May. 30 at 12:28 AM
1 · Reply
DaxCo
DaxCo May. 26 at 5:02 PM
$VALN https://finance.yahoo.com/sectors/healthcare/articles/lilly-acquire-three-vaccine-developers-105831332.html
0 · Reply
RustyShackleford_
RustyShackleford_ May. 19 at 12:28 AM
$VALN is this the right place to cash in on the deep states manufactured tick pandemic? Lemme know!!
1 · Reply
MarketBeat
MarketBeat May. 13 at 7:11 PM
https://marketbeat.com/a/8652863/ $VALN Valneva Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 13 at 2:00 PM
https://www.marketbeat.com/earnings/reports/2026-5-13-valneva-se-american-depositary-shares-stock/ $VALN Valneva Earnings Transcript
0 · Reply
DARKP00L
DARKP00L May. 13 at 12:02 PM
$VALN 07:14 on May. 13 2026 Valneva Lowers FY2026 Sales Guidance from $180.443M-$197.906M to $169.795M-$187.360M vs $192.800M Est #tradeideas
0 · Reply
Boonkers
Boonkers May. 13 at 5:31 AM
$VALN https://valneva.com/press-release/valneva-reports-first-quarter-2026-financial-results-and-provides-corporate-updates/
0 · Reply
buzzkiller
buzzkiller May. 12 at 10:26 AM
$VALN hot stinkin' garbage babbbby! time for a fat-cat shake-up! picking up more here to make my vote count.
0 · Reply
Skywulf
Skywulf May. 11 at 3:43 PM
$VALN up 16% and no news, definitely someone knows something we dont
0 · Reply
Pekri
Pekri May. 11 at 12:30 PM
$VALN up 10+% in Frankfurt on "strong" volume and no news? https://live.deutsche-boerse.com/equity/valneva-se?mic=XFRA
1 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 7:20 PM
$VALN Current Stock Price: $5.34
0 · Reply
Aurum81
Aurum81 Apr. 30 at 10:12 AM
$VALN The timing of the last two capital increases is really bad...
1 · Reply
Boonkers
Boonkers Apr. 30 at 5:29 AM
$VALN https://valneva.com/press-release/valneva-announces-the-successful-completion-of-a-e84-million-reserved-offering/
0 · Reply
Aurum81
Aurum81 Apr. 22 at 5:57 PM
$VALN A month ago tomorrow, Valneva surprised the market negatively with disappointing results, and the stock price hasn’t recovered at all since then. Today, Goldman Sachs is adding fuel to the fire, and the stock’s decline continues. It’s hard to believe, but better days/weeks/months are on the way 🍀
0 · Reply